Loading LLY detail
Loading ticker data...
Loading LLY detail
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide.
It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes. The company provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal cancers, and various head and neck cancers; Retevmo for metastatic NSCLC, medullary thyroid cancer, and thyroid cancer; Tyvyt for relapsed or refractory classic Hodgkin's lymph and non-squamous NSCLC; and Verzenio for HR+, HER2- metastatic breast cancer, node positive, and early breast cancer. It offers Olumiant for rheumatoid arthritis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis. The company offers Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Emgality for migraine prevention and episodic cluster headache; and Zyprexa for schizophrenia, bipolar I disorder, and bipolar maintenance. Its Bamlanivimab and etesevimab, and Bebtelovimab for COVID-19; Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis.
The company has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; Regor Therapeutics Group; Lycia Therapeutics, Inc.; Kumquat Biosciences Inc.; Entos Pharmaceuticals Inc.; and Foghorn Therapeutics Inc. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana.
Chart data unavailable
Eli Lilly and Company (NYSE:LLY | LLY Price Prediction) and Novo Nordisk A/S (NYSE:NVO) reported quarterly results in early February, and the gap between them has widened significantly.
Amazon (NASDAQ: AMZN | AMZN Price Prediction) just made a quiet move that could reshape how Americans access weight-loss drugs.
Apella Capital LLC boosted its holdings in shares of Eli Lilly and Company (NYSE: LLY) by 51.8% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 3,174 shares of the company's stock after purchasing an additional 1,083 shares
Eli Lilly's market share in India's weight‑loss drug market fell to 56% in March from 61% in February. Novo Nordisk's market share remained steady at 25%.
Representative Gilbert Ray Cisneros, Jr. (Democratic-California) recently sold shares of Eli Lilly and Company (NYSE: LLY). In a filing disclosed on April 07th, the Representative disclosed that they had sold between $1,001 and $15,000 in Eli Lilly and Company stock on March 13th. Representative Gilbert Ray Cisneros, Jr. also recently made the following trade(s): Purchased $15,001
The pharmaceutical's Foundayo drug takes on oral Wegovy, the popular treatment from Novo Nordisk.
CoreWeave (CRWV), Chevron (CVX), Eli Lilly (LLY), and Tesla (TSLA) are all in focus Thursday, each moving on very different headlines as markets open on a cauti
Eli Lilly (LLY) said its newly approved weight-loss pill Foundayo will be sold at U.S. retail pharmacies starting Thursday, giving Eli Lilly stock a fresh catal
Amazon.com said on Thursday its pharmacy unit will stock Eli Lilly's new weight-loss pill at kiosks located at some of the company's primary care clinics and offer same-day delivery of the drug.
Eli Lilly's Foundayo weight-loss pill is now available in the U.S. following the Food and Drug Administration's approval earlier this month, the company said.
STAAR Surgical (STAA) expects Q1 net sales to exceed $90M, more than doubling year-over-year, driven primarily by China and double-digit growth in the Americas. Disney plans 1,000 job cuts in marketing overhaul under new CEO.
Foundayo is now available via LillyDirect ® and telehealth providers and is shipping to retail pharmacies nationwide Foundayo, the only GLP-1 pill for weight loss that can be taken any time of day without food or water restrictions, starts at $25 per month with commercial coverage and $149 per month with self-pay INDIANAPOLIS, April 9, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that Foundayo™ (orforglipron) is now available to adults with obesity or overweight with weight-related medical problems following the U.S. Food and Drug Administration (FDA) approval on April 1, 2026. When used alongside a reduced-calorie diet and increased physical activity, Foundayo helps individuals lose excess body weight and keep the weight off.
Allen Mooney and Barnes Investment Advisors LLC grew its holdings in shares of Eli Lilly and Company (NYSE: LLY) by 12.4% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 5,755 shares of the company's stock after purchasing an additional 633 shares
In the most recent trading session, Eli Lilly (LLY) closed at $953.3, indicating a +2.39% shift from the previous trading day.
These two companies operate in a high-growth market, one that's heading toward $100 billion, according to analysts' forecasts. Their products have brought in blockbuster revenue.
